Get the Stockscreener App
6.87
1.43%
-0.10
Pre-market:
6.94
0.07
+1.02%
Telix Pharmaceuticals Ltd Adr stock is traded at $6.87, with a volume of 467.41K.
It is down -1.43% in the last 24 hours and down -3.65% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$6.97
Open:
$6.89
24h Volume:
467.41K
Relative Volume:
2.20
Market Cap:
$2.33B
Revenue:
$417.75M
Net Income/Loss:
$32.27M
P/E Ratio:
70.46
EPS:
0.0975
Net Cash Flow:
-
1W Performance:
+1.18%
1M Performance:
-3.65%
6M Performance:
-24.34%
1Y Performance:
-60.77%
1-Day Range:
$6.77
$6.91
1-Week Range:
$6.69
$7.52
52-Week Range:
$6.28
$20.00
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
6.87 | 2.36B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Citigroup | Buy |
| Aug-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-03-25 | Initiated | H.C. Wainwright | Buy |
| Jun-05-25 | Initiated | Wedbush | Outperform |
| Nov-15-24 | Initiated | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
Investor Education Webinar - GlobeNewswire Inc.
Global prostate scan registry taps AI to predict survival - Stock Titan
Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why - Finviz
Telix leaders to speak at Oppenheimer and TD Cowen, sessions streamed live - Stock Titan
Stock of the day: Telix Pharmaceuticals - ig.com
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Telix submits European marketing application for brain cancer imaging agent By Investing.com - Investing.com India
Telix Pharmaceuticals stock rises after European regulatory submission By Investing.com - Investing.com India
Sea Limited Sponsored ADR (SE) Rises Higher Than Market: Key Facts - Yahoo Finance
New Telix brain scan aims to distinguish tumor growth from treatment effects - Stock Titan
Are Investors Undervaluing Yankuang Energy Group Company Limited Sponsored ADR (YZCAY) Right Now? - Yahoo Finance
Here's Why PDD Holdings Inc. Sponsored ADR (PDD) Fell More Than Broader Market - Yahoo Finance
Sea Limited Sponsored ADR (SE) Advances While Market Declines: Some Information for Investors - Yahoo Finance
Is ANZ Group Holdings LimitedSponsored ADR (ANZGY) Outperforming Other Finance Stocks This Year? - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Li Auto Inc. Sponsored ADR (LI) Advances While Market Declines: Some Information for Investors - Yahoo Finance
XPeng Inc. Sponsored ADR (XPEV) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Sea Limited Sponsored ADR (SE) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RBC Capital upgrades Telix Pharmaceuticals stock rating to Outperform - Investing.com
Telix begins phase 3 trial to reduce prostate cancer biopsies - Investing.com South Africa
Telix Pharmaceuticals Within The Evolving Precision Oncology Space - Kalkine Media
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Sahm
Here's What Analysts Think About Telix Pharmaceuticals (TLX) - Finviz
Shareholders that lost money on Telix Pharmaceuticals Ltd.(TLX) should contact The Gross Law Firm about pending Class ActionTLX - Sahm
Telix Pharmaceuticals Ltd. Sued for Securities Law ViolationsContact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Barchart.com
Health conference talk to spotlight Telix therapeutic pipeline and products - Stock Titan
Sea Limited Sponsored ADR (SE) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
New Strong Buy Stocks for January 6th - Yahoo Finance
TLX 6-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures - Sahm
FCX IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Freeport-McMoRan Inc. Investors to Secure Counsel Before Important January 12 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. LawsuitTLX - Sahm
TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - Barchart.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX)January 9, 2026 Deadline to JoinContact Levi & Korsinsky - Sahm
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Stockholders to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Is Grupo Cibest S.A.Sponsored ADR (CIB) Stock Outpacing Its Conglomerates Peers This Year? - Yahoo Finance
Prostate scans reshaped treatment for 67% of men in China trial - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Finviz
Telix Pharma (TLX) Makes Progress With New Study - Finviz
RBC Capital initiates Telix Pharmaceuticals stock with Sector Perform rating - Investing.com
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):